Characteristics | All | Alive (N = 54) | Died (N = 16) | p-value | |||
(N = 70) | |||||||
No. | % | No. | % | No. | % | ||
Age (years) |
|
|
|
| |||
Mean ± SD | 50.24 ± 9.58 | 49.92 ± 9.57 | 51.31 ± 9.85 | 0.524 | |||
Median (Range) | 52.50 (27 - 62) | 52 (27 - 62) | 54 (28 - 61) | ||||
Grade |
|
|
|
|
|
|
|
Low | 18 | 27.7% | 16 | 88.9% | 2 | 11.1% | 0.209‡ |
High | 52 | 74.3% | 38 | 73.1% | 14 | 26.9% | |
LN |
|
|
|
|
|
|
|
Negative | 22 | 31.4% | 21 | 95.5% | 1 | 4.5% | 0.014‡ |
Positive | 48 | 68.6% | 33 | 68.8% | 15 | 31.2% | |
Stage |
|
|
|
|
|
|
|
Stage I | 8 | 11.4% | 8 | 100% | 0 | 0% | 0.056§ |
Stage II | 12 | 17.1% | 10 | 83.3% | 2 | 16.7% | |
Stage III | 32 | 45.7% | 24 | 75% | 8 | 25% | |
Stage IV | 18 | 25.7% | 12 | 66.7% | 6 | 33.3% | |
CA125 (u/ml) |
|
|
|
| |||
Mean ± SD | 1071.31 ± 666.91 | 960.01 ± 670.88 | 1446.93 ± 510.49 | 0.009 | |||
Median (Range) | 1238.50 (69 - 2008) | 1233.50 (69 - 2005) | 1253.50 (90 - 2008) | ||||
Gal-1 (ng/ml) |
|
|
|
| |||
Mean ± SD | 334.84 ± 187.67 | 296.25 ± 174.70 | 465.05 ± 175.31 | <0.001 | |||
Median (Range) | 277 (32 - 763) | 271 (32 - 649) | 380 (280 - 763) | ||||
Gal-1 |
|
|
|
|
|
|
|
Weak | 22 | 31.4% | 22 | 100% | 0 | 0% | 0.002‡ |
Strong | 48 | 68.6% | 32 | 66.7% | 16 | 33.3% | |
Gal-1 tumor cells |
|
|
|
|
|
|
|
Weak | 24 | 34.3% | 21 | 87.5% | 3 | 12.5% | 0.136‡ |
Strong | 46 | 65.7% | 33 | 71.7% | 13 | 28.3% |